Although there is only one FDA-approved anti-BAFF antibody, belimumab, which is used exclusively in rheumatology, new anti-BAFF antibodies are currently being tested for treatment of B-cell lymphomas [87]. Here, TNFSF13B is linked to B-cell non-Hodgkin lymphoma.